ITMI20031714A1 - Formazioni ad azione antitumorale. - Google Patents

Formazioni ad azione antitumorale.

Info

Publication number
ITMI20031714A1
ITMI20031714A1 IT001714A ITMI20031714A ITMI20031714A1 IT MI20031714 A1 ITMI20031714 A1 IT MI20031714A1 IT 001714 A IT001714 A IT 001714A IT MI20031714 A ITMI20031714 A IT MI20031714A IT MI20031714 A1 ITMI20031714 A1 IT MI20031714A1
Authority
IT
Italy
Prior art keywords
formations
antitumoral action
antitumoral
action
formulations
Prior art date
Application number
IT001714A
Other languages
English (en)
Italian (it)
Inventor
Laura Iris Ferro
Paul Richardson
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Priority to IT001714A priority Critical patent/ITMI20031714A1/it
Priority to PCT/EP2004/009723 priority patent/WO2005023273A1/en
Priority to CNB2004800253315A priority patent/CN100490820C/zh
Priority to JP2006525096A priority patent/JP4671962B2/ja
Priority to ES04764686T priority patent/ES2308223T3/es
Priority to ZA200601852A priority patent/ZA200601852B/en
Priority to CA2537226A priority patent/CA2537226C/en
Priority to YUP-2006/0154A priority patent/RS20060154A/sr
Priority to DK04764686T priority patent/DK1660100T3/da
Priority to DE602004014787T priority patent/DE602004014787D1/de
Priority to PT04764686T priority patent/PT1660100E/pt
Priority to AU2004269896A priority patent/AU2004269896B2/en
Priority to UAA200602374A priority patent/UA83500C2/uk
Priority to RU2006109210/15A priority patent/RU2348413C2/ru
Priority to KR1020067004451A priority patent/KR20060061367A/ko
Priority to AT04764686T priority patent/ATE399558T1/de
Priority to MXPA06002489A priority patent/MXPA06002489A/es
Priority to EP04764686A priority patent/EP1660100B1/en
Priority to BRPI0414114-8A priority patent/BRPI0414114A/pt
Publication of ITMI20031714A1 publication Critical patent/ITMI20031714A1/it
Priority to IL173785A priority patent/IL173785A0/en
Priority to IS8334A priority patent/IS8334A/is
Priority to US11/366,243 priority patent/US8551967B2/en
Priority to NO20061402A priority patent/NO20061402L/no
Priority to US14/019,674 priority patent/US20140005256A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IT001714A 2003-09-05 2003-09-05 Formazioni ad azione antitumorale. ITMI20031714A1 (it)

Priority Applications (24)

Application Number Priority Date Filing Date Title
IT001714A ITMI20031714A1 (it) 2003-09-05 2003-09-05 Formazioni ad azione antitumorale.
UAA200602374A UA83500C2 (uk) 2003-09-05 2004-08-27 Застосування дефібротиду як протипухлинного агента самостійно або в поєднанні з іншими протипухлинними агентами
AU2004269896A AU2004269896B2 (en) 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
JP2006525096A JP4671962B2 (ja) 2003-09-05 2004-08-27 デフィブロチド単独又は他の抗腫瘍剤との組み合わせを含む抗腫瘍製剤
ES04764686T ES2308223T3 (es) 2003-09-05 2004-08-27 Formulaciones antitum0rales que comprenden defibrotido solo o en combinacion con otros agentes antitumorales.
ZA200601852A ZA200601852B (en) 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
CA2537226A CA2537226C (en) 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
CNB2004800253315A CN100490820C (zh) 2003-09-05 2004-08-27 单独包含去纤苷酸或与其它抗肿瘤剂联合的抗肿瘤制剂
DK04764686T DK1660100T3 (da) 2003-09-05 2004-08-27 Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler
DE602004014787T DE602004014787D1 (de) 2003-09-05 2004-08-27 Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
PT04764686T PT1660100E (pt) 2003-09-05 2004-08-27 Formulações antitumorais compreendendo defibrotida sozinha ou em combinação com outros agentes antitumorais
PCT/EP2004/009723 WO2005023273A1 (en) 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
YUP-2006/0154A RS20060154A (sr) 2003-09-05 2004-08-27 Anti-tumorske formulacije koje sadrže defibrotid, sam ili u kombinaciji sa drugim anti-tumorskim sredstvima
EP04764686A EP1660100B1 (en) 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
KR1020067004451A KR20060061367A (ko) 2003-09-05 2004-08-27 디파이브로타이드를 단독으로 또는 다른 항암제들과조합하여 포함하는 항암제제
AT04764686T ATE399558T1 (de) 2003-09-05 2004-08-27 Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
MXPA06002489A MXPA06002489A (es) 2003-09-05 2004-08-27 Formulaciones anti-tumorales que contienen defibrotido solo o en combinacion con otros agentes anti-tumorales.
RU2006109210/15A RU2348413C2 (ru) 2003-09-05 2004-08-27 Противоопухолевые лекарственные составы, содержащие дефибротид, один или в сочетании с другими противоопухолевыми средствами
BRPI0414114-8A BRPI0414114A (pt) 2003-09-05 2004-08-27 uso de defibrotide, formulação, e, método para tratar um mamìfero afetado por um tumor
IL173785A IL173785A0 (en) 2003-09-05 2006-02-16 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
IS8334A IS8334A (is) 2003-09-05 2006-02-28 Æxilseyðandi samsetningar sem samanstanda af defíbrótíði stöku eða blönduðu með öðrum æxliseyðandi miðlum
US11/366,243 US8551967B2 (en) 2003-09-05 2006-03-02 Formulations with anti-tumour action
NO20061402A NO20061402L (no) 2003-09-05 2006-03-28 Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler
US14/019,674 US20140005256A1 (en) 2003-09-05 2013-09-06 Formulations with anti-tumour action

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001714A ITMI20031714A1 (it) 2003-09-05 2003-09-05 Formazioni ad azione antitumorale.

Publications (1)

Publication Number Publication Date
ITMI20031714A1 true ITMI20031714A1 (it) 2005-03-06

Family

ID=37064585

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001714A ITMI20031714A1 (it) 2003-09-05 2003-09-05 Formazioni ad azione antitumorale.

Country Status (23)

Country Link
US (2) US8551967B2 (enExample)
EP (1) EP1660100B1 (enExample)
JP (1) JP4671962B2 (enExample)
KR (1) KR20060061367A (enExample)
CN (1) CN100490820C (enExample)
AT (1) ATE399558T1 (enExample)
AU (1) AU2004269896B2 (enExample)
BR (1) BRPI0414114A (enExample)
CA (1) CA2537226C (enExample)
DE (1) DE602004014787D1 (enExample)
DK (1) DK1660100T3 (enExample)
ES (1) ES2308223T3 (enExample)
IL (1) IL173785A0 (enExample)
IS (1) IS8334A (enExample)
IT (1) ITMI20031714A1 (enExample)
MX (1) MXPA06002489A (enExample)
NO (1) NO20061402L (enExample)
PT (1) PT1660100E (enExample)
RS (1) RS20060154A (enExample)
RU (1) RU2348413C2 (enExample)
UA (1) UA83500C2 (enExample)
WO (1) WO2005023273A1 (enExample)
ZA (1) ZA200601852B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531647A (ja) * 2005-03-03 2008-08-14 ゲンチウム エスピーエー 抗腫瘍作用を有する製剤
EP1872787A1 (en) * 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
US10380734B2 (en) * 2017-02-27 2019-08-13 Aniket Bharat Parikh System, method and computer program product for security analysis of jewelry items
SG11202000952PA (en) * 2017-08-03 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Formulations comprising a nucleic acid in a high concentration
MX2020010689A (es) 2018-04-12 2021-01-20 Jazz Pharmaceuticals Inc Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
US20230190783A1 (en) 2020-02-28 2023-06-22 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) * 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) * 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
IT1190313B (it) * 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5223609A (en) * 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE9202745U1 (de) 1992-03-02 1992-04-30 Howmedica Gmbh, 2314 Schoenkirchen Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
JP2002512508A (ja) 1997-05-30 2002-04-23 マクギル・ユニヴァーシティ Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
EP1206234A4 (en) * 1999-06-03 2005-06-01 Jessie L S Au METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH
JP2005503756A (ja) * 2000-12-29 2005-02-10 サビエント ファーマシューティカルズ，インコーポレイティド 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
US7514414B2 (en) 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
HRP20041213A2 (hr) * 2002-05-31 2006-04-30 Klinikum der Universit�t Regensburg Postupci zaštite endotelnih i epitelnih stanica tijekom kemoterapije
RU2005101621A (ru) * 2002-07-01 2005-11-20 Савиент Фармасьютикалс, Инк. (Us) Антитела и их применения
CN100345593C (zh) 2002-08-06 2007-10-31 东丽株式会社 用于制备肾脏疾病的治疗或预防药物中的用途
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
JP2008531647A (ja) 2005-03-03 2008-08-14 ゲンチウム エスピーエー 抗腫瘍作用を有する製剤
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases

Also Published As

Publication number Publication date
WO2005023273A1 (en) 2005-03-17
IS8334A (is) 2006-02-28
EP1660100A1 (en) 2006-05-31
NO20061402L (no) 2006-03-28
DK1660100T3 (da) 2008-11-10
US8551967B2 (en) 2013-10-08
ZA200601852B (en) 2007-06-27
US20060211646A1 (en) 2006-09-21
UA83500C2 (uk) 2008-07-25
KR20060061367A (ko) 2006-06-07
CA2537226A1 (en) 2005-03-17
ATE399558T1 (de) 2008-07-15
PT1660100E (pt) 2008-10-14
RU2006109210A (ru) 2007-10-10
IL173785A0 (en) 2006-07-05
RU2348413C2 (ru) 2009-03-10
JP2007504194A (ja) 2007-03-01
CN1845746A (zh) 2006-10-11
AU2004269896B2 (en) 2009-11-19
CA2537226C (en) 2016-05-03
AU2004269896A1 (en) 2005-03-17
RS20060154A (sr) 2008-08-07
ES2308223T3 (es) 2008-12-01
US20140005256A1 (en) 2014-01-02
CN100490820C (zh) 2009-05-27
MXPA06002489A (es) 2006-06-20
EP1660100B1 (en) 2008-07-02
DE602004014787D1 (de) 2008-08-14
BRPI0414114A (pt) 2006-10-31
JP4671962B2 (ja) 2011-04-20

Similar Documents

Publication Publication Date Title
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
ATE376996T1 (de) Antibakterielle mittel
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
ATE461217T1 (de) Glp-1-verbindungen
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
BRPI0508894A (pt) meios para administração transdérmica de nicotina e uso
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
DK1330258T3 (da) Kahalalid F-formulering
ITMI20030385A1 (it) Composizione cosmetica comprendente poliisoprene.
MX2009012370A (es) Formulacion de antraciclina de baja viscosidad.
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
NO20063393L (no) Farmasoytiske preparater
DE50310323D1 (de) Wässrige polyurethanzubereitungen
BRPI0417265A (pt) composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna
TW200621160A (en) Anti-termite agent
TW200509794A (en) Novel anthelmintic and insecticidal compositions
BRPI0417205A (pt) composições farmacêuticas
DK1713438T3 (da) Medicinsk sæbe
GB0327390D0 (en) Pharmaceutical formulations
NO20065791L (no) Asyklovir-formuleringer
GB0423008D0 (en) Organic compounds
ITTO20020406A1 (it) Formulazioni di bisfosfonati ad uso iniettabile.
BRPI0414248A (pt) 4-metildec-4-en-3-ol e composição de fragráncia
UA4196U (uk) Поліфіт-прополіс - біологічно активна домішка для профілактики та лікування інфекційних захворювань, туберкульозу, виразкової хвороби, підвищення імунітету
ITMI20011561A0 (it) Nuove composizioni con fosfolipidi biologicamente attivi